Valenzuela Pedro, Sanz J Miguel, Keller Jerry
Servicio de Obstetricia y Ginecología Hospital Universitario Príncipe de Asturias, Madrid, España.
Gynecol Obstet Invest. 2003;56(3):163-7. doi: 10.1159/000073950. Epub 2003 Oct 7.
The diagnoses of atypical hyperplasia and well-differentiated adenocarcinoma imply totally different approaches because of clinical and patient-oriented ramifications, especially when morphological differences are not entirely conclusive. The purpose of this study was to examine the relationship between the diagnosis of atypical hyperplasia during curettage or endometrial biopsy and the definitive histological findings from hysterectomy material.
23 patients were found fit for the current study and subsequently their clinical histories were reviewed for relevant clinical data, histopathological profiling and type of therapeutic interventions.
Adenocarcinoma was observed in 12 (52.17%) of 23 hysterectomy cases. The hyperplasia was found in 10 (43.47%) cases, although 4 of them lacked atypia and 1 case proved to be hyperplasia-free.
Hysterectomy was prescribed as the next step in the diagnosis of atypical endometrial hyperplasia. Other wait-and-see approaches could have easily forfeited the chances of providing an adequate treatment for an operable and curable cancer in approximately half of the studied cases.
非典型增生和高分化腺癌的诊断意味着完全不同的处理方法，因为它们会产生临床和以患者为导向的影响，尤其是当形态学差异并不完全确定时。本研究的目的是探讨刮宫术或子宫内膜活检时非典型增生的诊断与子宫切除标本最终组织学结果之间的关系。
发现23例患者适合本研究，随后回顾了他们的临床病史以获取相关临床数据、组织病理学特征及治疗干预类型。
23例子宫切除病例中，12例（52.17%）观察到腺癌。10例（43.47%）发现有增生，不过其中4例无细胞异型性，1例证实无增生。
子宫切除术被指定为非典型子宫内膜增生诊断的下一步措施。在大约一半的研究病例中，其他观望方法可能轻易错失为可手术治愈的癌症提供充分治疗的机会。
